News Release

Prescient Medicine Holdings is Now SOLVD Health

SOLVD Health’s mission is to prevent disease by making actionable health information accessible to everyone

CARLSBAD, Calif., December 1, 2020 – Prescient Medicine Holdings, Inc., a privately held company focused on developing insights-based health tools, today announced its rebrand to SOLVD Health. The new name and brand reflect the company’s mission to solve some of healthcare’s biggest challenges through preventative health solutions that combine genetics-based patient insights with cutting-edge technologies.

“As we drive toward commercialization of our two breakthrough tests for opioid use disorder and colon cancer, we believe the time is right to evolve our brand to reflect the current and future potential of our innovation platform,” said Keri Donaldson, M.D., Chief Executive Officer of SOLVD Health. “At SOLVD Health, our goal is to create much-needed predictive and actionable health insight tools and make them available to healthcare providers and their patients.”

SOLVD Health will focus on the development and commercialization of its innovative technologies, which utilize machine learning and custom algorithms. These technologies include two groundbreaking tests, which have both been granted Breakthrough Device designations by the U.S. Food and Drug Administration (FDA). One is a genetic test designed to identify people at increased risk for opioid use disorder (OUD) prior to taking oral prescription opioids. The other test analyzes an individual’s microbiome and is designed to detect colorectal cancer and precancerous adenomas.

“At SOLVD Health, we aim to prevent people from becoming patients,” said Dr. Donaldson. “By providing contextualized insights before symptoms occur – a model that we call Patient Intelligence – we can improve patients’ lives while also changing how we think about and conduct healthcare as a society.”

To learn more, visit the new SOLVD Health website at www.solvdhealth.com.

About SOLVD Health

SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, we are enabling individuals and their providers to make better decisions about their health and the health of their families. We accomplish this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about us, our solutions, and our career opportunities, visit us on LinkedIn or at www.solvdhealth.com.

Media Contact:
Valerie Melucci; pr@solvdhealth.com 

 

SOLVD Health’s Pharmacogenomics Test Receives New York State Department of Health Approval

SOLVD Health’s Pharmacogenomics Test Receives New York State Department of Health Approval

December 17, 2025 — SOLVD Health, a patient intelligence company pioneering precision medicine through advanced genetics and AI-driven insights, announced today that its pharmacogenomics (PGx) test PreScript™ has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP). This milestone enables SOLVD Health to offer its PGx testing services to healthcare providers and patients across New York State, one of the most rigorously regulated laboratory markets in the nation.

read more
SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

December 15, 2025 — SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has published a peer-reviewed article in the International Journal of Molecular Sciences on best practices for the clinical use of genome-wide association study (GWAS) data. The article provides guidance for integrating imputed genetic information into healthcare in a way that supports accuracy, transparency, and clinical utility.

read more
SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response

SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response

December 9, 2025 – SOLVD Health is launching two studies to validate our GLP‑1 patient stratification platform, bringing precision medicine to obesity and type 2 diabetes care. “As the worldwide prevalence of obesity and type 2 diabetes continues to grow, the need for more targeted, personalized treatment methods becomes increasingly critical,” Dr. Keri Donaldson, Founder and President, SOLVD Health.

read more